Aptose Biosciences (APS) Competitors C$1.68 -0.02 (-1.18%) As of 08/1/2025 04:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesBuy This Stock APS vs. PLI, ABCN, EMC, FRX, BCT, IPA, TH, ONC, SCYB, and COMShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), and 138267 (COM.TO) (COM). These companies are all part of the "biotechnology" industry. Aptose Biosciences vs. Its Competitors ProMetic Life Sciences VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Aptose Biosciences (TSE:APS) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Does the media prefer APS or PLI? In the previous week, Aptose Biosciences had 2 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for ProMetic Life Sciences. Aptose Biosciences' average media sentiment score of 0.03 beat ProMetic Life Sciences' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the media. Company Overall Sentiment Aptose Biosciences Neutral ProMetic Life Sciences Neutral Do analysts rate APS or PLI? Given ProMetic Life Sciences' higher probable upside, analysts plainly believe ProMetic Life Sciences is more favorable than Aptose Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00ProMetic Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APS or PLI more profitable? Aptose Biosciences' return on equity of 1,017.48% beat ProMetic Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Aptose BiosciencesN/A 1,017.48% -136.29% ProMetic Life Sciences N/A N/A N/A Which has stronger earnings & valuation, APS or PLI? Aptose Biosciences has higher earnings, but lower revenue than ProMetic Life Sciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.33ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A Do insiders & institutionals believe in APS or PLI? 15.1% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAptose Biosciences beats ProMetic Life Sciences on 9 of the 13 factors compared between the two stocks. Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APS vs. The Competition Export to ExcelMetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$72.34MC$134.47MC$5.47BC$6.20BDividend Yield0.39%3.74%4.74%6.72%P/E Ratio-0.333.7828.6763.43Price / SalesN/A4,246.60422.261,251.00Price / Cash1.6013.1935.4583.29Price / Book-1.8339.388.274.87Net Income-C$154.69M-C$90.99MC$3.24BC$301.20M7 Day Performance-25.99%-1.80%-3.63%-2.26%1 Month Performance40.00%11.27%4.40%0.81%1 Year Performance-91.52%189.85%25.97%26.63% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APSAptose BiosciencesN/AC$1.68-1.2%N/A-92.3%C$72.34MN/A-0.3331News CoverageGap UpPLIProMetic Life SciencesN/AN/AN/AN/AC$317.06MC$39.91M-0.22487ABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$11.74-2.1%N/A+27.4%C$226.40MC$34.86M-198.8710Gap DownBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$4.29-0.2%N/A+121.4%C$136.87MC$52.22M-48.56103ONCOncolytics Biotech1.2289 of 5 starsC$1.61-3.6%C$3.50+117.4%-7.4%C$124.09MN/A-4.4929Positive NewsSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/A Related Companies and Tools Related Companies PLI Competitors ABCN Competitors EMC Competitors FRX Competitors BCT Competitors IPA Competitors TH Competitors ONC Competitors SCYB Competitors COM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:APS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
